Treg cells: Collection, processing, storage and clinical use

Daniele, Nicola Di; Scerpa, Maria Cristina; Landi, Fabiola; Caniglia, Maurizio; Miele, Massimino Jan; Locatelli, Franco; Isacchi, G; Zinno, Francesco

doi:10.1016/j.prp.2011.02.003

Cited by 16 publications

(21 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Certainly, progress in understanding Treg cells biology and the optimization of protocols of Treg cells manipulation will promote the translation of researchbased knowledge to the clinic [10].…”

Section: Discussionmentioning

confidence: 99%

Hematopoietic Stem Cell Transplantation: Evolution and Future Perspectives

Daniele¹,

Zinno²

2015

Int J Lab Med Res

Self Cite

View full text Add to dashboard Cite

Hematopoietic stem cell transplantation is commonly used to treat several oncohematologic disease. The critical importance of cell dose in the clinical outcome, after transplant, has motivated the need to develop techniques aimed at reducing cell losses and increasing reproducibility.Moreover, it has been clearly demonstrated that T-cells in a graft are directly correlated to the risk of developing a life-threatening GvHD in allotransplanted patients. Different techniques have been employed for this purpose, including physical, immunological and combined immunological/physical methods with different results in terms of purity, recovery, and time consumption.To find new methods of cell manipulation is on of the most ambitious challenges in the field of stem cell transplantation.

show abstract

Section: Discussionmentioning

confidence: 99%

Hematopoietic Stem Cell Transplantation: Evolution and Future Perspectives

Daniele¹,

Zinno²

2015

Int J Lab Med Res

Self Cite

View full text Add to dashboard Cite

show abstract

“…These experimental data gave support to the potential use of Tregs in clinical transplantation. Many strategies exist for the ex vivo generation and⁄or expansion of Tregs[35,48-50]. Currently, three main approaches are being explored for Tregs expansion in the perspective of therapeutic protocols: ex vivo nTregs expansion, ex vivo conversion of naïve T cells to iTregs and in vivo expansion of nTregs and/or induction of iTregs[51-53].…”

Section: Regulatory T Cells In Transplantation and Tolerancementioning

confidence: 99%

Tolerance in liver transplantation: Biomarkers and clinical relevance

Baroja‐Mazo¹,

Revilla-Nuin²,

Parrilla³

et al. 2016

WJG

View full text Add to dashboard Cite

Transplantation is the optimal treatment for end-stage organ failure, and modern immunosuppression has allowed important progress in short-term outcomes. However, immunosuppression poorly influences chronic rejection and elicits chronic toxicity in current clinical practice. Thus, a major goal in transplantation is to understand and induce tolerance. It is well established that human regulatory T cells expressing the transcription factor FoxP3 play important roles in the maintenance of immunological self-tolerance and immune homeostasis. The major regulatory T cell subsets and mechanisms of expansion that are critical for induction and long-term maintenance of graft tolerance and survival are being actively investigated. Likewise, other immune cells, such as dendritic cells, monocyte/macrophages or natural killer cells, have been described as part of the process known as “operational tolerance”. However, translation of these results towards clinical practice needs solid tools to identify accurately and reliably patients who are going to be tolerant. In this way, a plethora of genetic and cellular biomarkers is raising and being validated worldwide in large multi-center clinical trials. Few of the studies performed so far have provided a detailed analysis of the impact of immunosuppression withdrawal on pre-existing complications derived from the long-term administration of immunosuppressive drugs and the side effects associated with them. The future of liver transplantation is aimed to develop new therapies which increase the actual low tolerant vs non-tolerant recipients ratio.

show abstract

“…Besides transfer of autologous, ex vivo enriched regulatory T-cells, therapeutic expansion/activation in vivo might be more promising [31, 114]. Mucosal application of antigens is able to potently induce regulatory T-cells with specificity against it.…”

Section: New Translational Targetsmentioning

confidence: 99%

How can we cure a heart “in flame”? A translational view on inflammation in heart failure

Hofmann

Frantz

2013

Basic Res Cardiol

View full text Add to dashboard Cite

The prevalence of chronic heart failure is still increasing making it a major health issue in the 21st century. Tremendous evidence has emerged over the past decades that heart failure is associated with a wide array of mechanisms subsumed under the term “inflammation”. Based on the great success of immuno-suppressive treatments in auto-immunity and transplantation, clinical trials were launched targeting inflammatory mediators in patients with chronic heart failure. However, they widely lacked positive outcomes. The failure of the initial study program directed against tumor necrosis factor-α led to the search for alternative therapeutic targets involving a broader spectrum of mechanisms besides cytokines. We here provide an overview of the current knowledge on immune activation in chronic heart failure of different etiologies, summarize clinical studies in the field, address unresolved key questions, and highlight some promising novel therapeutic targets for clinical trials from a translational basic science and clinical perspective.

show abstract

Treg cells: Collection, processing, storage and clinical use

Cited by 16 publications

References 73 publications

Hematopoietic Stem Cell Transplantation: Evolution and Future Perspectives

Hematopoietic Stem Cell Transplantation: Evolution and Future Perspectives

Tolerance in liver transplantation: Biomarkers and clinical relevance

How can we cure a heart “in flame”? A translational view on inflammation in heart failure

Contact Info

Product

Resources

About